K212957 is an FDA 510(k) clearance for the BioButton System. Classified as Transmitters And Receivers, Physiological Signal, Radiofrequency (product code DRG), Class II - Special Controls.
Submitted by Biolntellisense, Inc. (Redwood City, US). The FDA issued a Cleared decision on December 12, 2022 after a review of 452 days - an unusually long review period, suggesting complex equivalence evaluation.
This device falls under the Cardiovascular FDA review panel, regulated under 21 CFR 870.2910 - the FDA cardiovascular device oversight framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.
Device pattern: High-complexity regulatory submission. Elevated predicate reliance profile. The extended review timeline suggests the FDA required additional documentation before confirming substantial equivalence - a pattern common in complex or first-of-kind Cardiovascular submissions.
View all Biolntellisense, Inc. devices